Log in

Relevant bibliographies by topics / 35 [74.4%] survived with 18 / Journal articles

To see the other types of publications on this topic, follow the link: 35 [74.4%] survived with 18.

Journal articles on the topic '35 [74.4%] survived with 18'

Author: Grafiati

Published: 3 June 2025

Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic '35 [74.4%] survived with 18.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Bojanini Molina, Leyla, Muhamad Alhaj Moustafa, Ricardo Daniel Parrondo, et al. "Hepatosplenic T-cell lymphoma: The Mayo Clinic experience." Journal of Clinical Oncology 38, no. 15_suppl (2020): e20036-e20036. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.e20036.

Full text

Abstract:

e20036 Background: Hepatosplenic T cell lymphoma (HSTL) is a rare subtype of mature T cell lymphomas accounting for less than 1 percent of non-Hodgkin lymphomas. it has been associated with poor prognosis. It typically involves sinusoids in the spleen, liver, and bone marrow. Methods: Following IRB approval, we retrospectively evaluated patients with HSTL treated at the Mayo Clinic Cancer Center 1996-2019. Kaplan-Meier survival analysis and univariate analysis to identify prognostic factors were performed. We investigated clinical characteristics and outcomes among patients with HSTL. Results:

APA, Harvard, Vancouver, ISO, and other styles

2

Dao, Vi, Morel Rubinger, Eric J. Bow, et al. "Epidemiology of Adult Acute Lymphoblastic Leukemia in Manitoba, Canada: Does This Approximate Clinical Trial Data?." Blood 106, no. 11 (2005): 4554. http://dx.doi.org/10.1182/blood.v106.11.4554.4554.

Full text

Abstract:

Abstract Background: Outcomes of unselected adult ALL patients (pts) have not been well studied at a population level. Whether such pts behave differently to those in formal clinical trials is unclear. We developed a uniform therapeutic protocol as the provincial standard of care in Manitoba, a province with 1.2 million people, for adult pts since 1989 (“ALL89-1”). The aim of this retrospective study was: to ascertain the local epidemiology of adult ALL; to analyze the efficacy and toxicity of the ALL89-1 regimen and any other regimens given to pts in a population-based setting. Methods: All p

APA, Harvard, Vancouver, ISO, and other styles

3

Blackstock, A. W., M. A. Socinski, J. Bogart, et al. "Induction (Ind) plus concurrent (Con) chemotherapy with high-dose (74 Gy) 3-dimensional (3-D) thoracic radiotherapy (TRT) in stage III non-small cell lung cancer (NSCLC): Preliminary report of Cancer and Leukemia Group B (CALGB) 30105." Journal of Clinical Oncology 24, no. 18_suppl (2006): 7042. http://dx.doi.org/10.1200/jco.2006.24.18_suppl.7042.

Full text

Abstract:

7042 Background: Combined chemoradiotherapy is the standard of care in stage III NSCLC. At standard TRT doses, local failures remain problematic and strategies exploiting the dose-response aspect of TRT are warranted. 3-D TRT allows escalation of TRT dose with acceptable toxicity (Socinski et al, J Clin Oncol 22:4341, 2004) and may enhance survival by improving loco-regional control. Methods: This is a two-arm randomized phase II trial evaluating 74 Gy with Con chemotherapy: Arm A- 2 cycles of Ind carboplatin (C) (AUC 6) and paclitaxel (P) (225 mg/m2) followed by weekly Con C (AUC 2/wk) and P

APA, Harvard, Vancouver, ISO, and other styles

4

Pasini, F., G. de Manzoni, L. Stievano, et al. "Effect of neoadjuvant combined modality therapy with weekly docetaxel (D) and cisplatin (P), 5-fluorouracil (5-FU) continuous infusion (c.i.), and concurrent radiotherapy (RT) on pathological response rate in esophageal cancers (EC): A phase II study." Journal of Clinical Oncology 27, no. 15_suppl (2009): 4548. http://dx.doi.org/10.1200/jco.2009.27.15_suppl.4548.

Full text

Abstract:

4548 Background: The achievement of pathological complete response (pCR) seems essential to improve survival in EC. In a phase I study (Pasini et al, Ann Oncol 2005) we demonstrated the feasibility of a novel protocol of neoadjuvant chemoradiation. Based on these promising results, we have performed a phase II study. The primary end point was the pathological response rate, the secondary end points were survival and toxicity. Methods: 74 pts with stage II-III EC (37 adenocarcinomas) were enrolled; median age was 59 yrs (42–73). Treatment consisted of D 35 mg/m2 and P 25 mg/m2 d 1,8,15,29,36,43

APA, Harvard, Vancouver, ISO, and other styles

5

Jabbour, Elias, Marcos De Lima, Leandro de Padua Silva, et al. "Long-Term Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Patients (pts) with Advanced Chronic Myeloid Leukemia (CML) Post Imatinib Failure." Blood 112, no. 11 (2008): 979. http://dx.doi.org/10.1182/blood.v112.11.979.979.

Full text

Abstract:

Abstract Allogeneic HSCT is a potentially curative treatment for pts with CML, and is effective after imatinib failure. We assessed the long-term results of HSCT in 92 consecutive pts with CML that had failed imatinib. Herein are the results of this review. Preparative regimens were reduced-intensity intravenous (IV) busulfan (Bu)-fludarabine (Flu) in 40 pts, IV Bu-cyclophosphamide in 39, Flu-melphalan in 6, and total body irradiation (TBI) based regimens in 7. Graft-versus-host disease (GVHD) prophylaxis consisted of tacrolimus and mini-methotrexate 5 mg/m2. Donors were matched related in 49

APA, Harvard, Vancouver, ISO, and other styles

6

Horiike, A., F. Ohyanagi, Y. Okano, et al. "A feasibility study of adjuvant carboplatin (C) plus gemcitabine (G) in completely resected stage IB-III non-small-cell lung cancer (NSCLC)." Journal of Clinical Oncology 25, no. 18_suppl (2007): 18158. http://dx.doi.org/10.1200/jco.2007.25.18_suppl.18158.

Full text

Abstract:

18158 Background: In recent randomized phase III trials in early-stage NSCLC, cisplatin-based adjuvant chemotherapy resulted in a 4.1–15% 5-year survival benefit versus observation. However, only 56–74% of patients completed planned treatment, suggestive of poor compliance. C plus G (CG), one of the standard regimens for advanced NSCLC, is considered more tolerable than other platinum-based regimens because it is associated with less nausea/vomiting, sensory neuropathy, and alopecia. The objective of this study was to assess the feasibility and safety of adjuvant CG in patients with completely

APA, Harvard, Vancouver, ISO, and other styles

7

Hügli, A., D. Moro, B. Mermillod, et al. "Phase II Trial of Up-Front Accelerated Thoracic Radiotherapy Combined With Chemotherapy and Optional Up-Front Prophylactic Cranial Irradiation in Limited Small-Cell Lung Cancer." Journal of Clinical Oncology 18, no. 8 (2000): 1662–67. http://dx.doi.org/10.1200/jco.2000.18.8.1662.

Full text

Abstract:

PURPOSE: To investigate the feasibility and outcome of bifractionated, up-front thoracic radiotherapy (TR) (45 Gy in 30 fractions of 1.5 Gy twice daily over 3 weeks) combined with chemotherapy (CT) (six cycles of cisplatin and etoposide) and optional low-dose, up-front prophylactic cranial irradiation (18 Gy in 10 fractions of 1.8 Gy twice daily over 5 days) in limited small-cell lung cancer. PATIENTS AND METHODS: CT (etoposide 100 mg/m2 for 3 days and cisplatin 25 mg/m2 for 3 days) was started on day 8 or 15 after the first TR treatment. In the five subsequent cycles, cisplatin was given as a

APA, Harvard, Vancouver, ISO, and other styles

8

Grelier, Laure, Michael Baboudjian, Bastien Gondran-Tellier, et al. "Stereotactic Body Radiotherapy for Frail Patients with Primary Renal Cell Carcinoma: Preliminary Results after 4 Years of Experience." Cancers 13, no. 13 (2021): 3129. http://dx.doi.org/10.3390/cancers13133129.

Full text

Abstract:

Introduction: The aim of this study was to report the oncological outcomes and toxicity of stereotactic body radiotherapy (SBRT) to treat primary renal cell carcinoma (RCC) in frail patients unfit for surgery or standard alternative ablative therapies. Methods: We retrospectively enrolled 23 patients who had SBRT for primary, biopsy-proven RCC at our tertiary center between October 2016 and March 2020. Treatment-related toxicities were defined using CTCAE, version 4.0. The primary outcome was local control which was defined using the Response Evaluation Criteria in Solid Tumors. Results: The m

APA, Harvard, Vancouver, ISO, and other styles

9

Socinski, Mark A., A. William Blackstock, Jeffrey A. Bogart, et al. "Randomized Phase II Trial of Induction Chemotherapy Followed by Concurrent Chemotherapy and Dose-Escalated Thoracic Conformal Radiotherapy (74 Gy) in Stage III Non–Small-Cell Lung Cancer: CALGB 30105." Journal of Clinical Oncology 26, no. 15 (2008): 2457–63. http://dx.doi.org/10.1200/jco.2007.14.7371.

Full text

Abstract:

PurposeTo evaluate 74 Gy thoracic radiation therapy (TRT) with induction and concurrent chemotherapy in stage IIIA/B non–small-cell lung cancer (NSCLC).Patients and MethodsPatients with stage IIIA/B NSCLC were randomly assigned to induction chemotherapy with either carboplatin (area under the curve [AUC], 6; days 1 and 22) with paclitaxel (225 mg/m2; days 1 and 22; arm A) or carboplatin (AUC, 5; days 1 and 22) with gemcitabine (1,000 mg/m2; days 1, 8, 22, and 29; arm B). On day 43, arm A received weekly carboplatin (AUC, 2) and paclitaxel (45 mg/m2) while arm B received biweekly gemcitabine (3

APA, Harvard, Vancouver, ISO, and other styles

10

Proctor, Stephen J., Jennifer Wilkinson, Gail Jones, et al. "Evaluation of treatment outcome in 175 patients with Hodgkin lymphoma aged 60 years or over: the SHIELD study." Blood 119, no. 25 (2012): 6005–15. http://dx.doi.org/10.1182/blood-2011-12-396556.

Full text

Abstract:

Abstract The SHIELD program for Hodgkin lymphoma in patients 60 years of age or older, prospectively evaluated clinical features and outcome in a large patient cohort (n = 175). The central element was a phase 2 study of VEPEMB chemotherapy (n = 103, median age 73 years) incorporating comorbidity assessment. A total of 72 other patients were treated off-study but registered prospectively and treated concurrently with: ABVD (n = 35); CLVPP (n = 19), or other (n = 18). Of VEPEMB patients, 31 had early-stage disease (stage 1A/2A) and received VEPEMB 3 times plus radiotherapy. Median follow-up was

APA, Harvard, Vancouver, ISO, and other styles

11

Londero, Francesco, William Grossi, Orlando Parise, et al. "The Impact of Preoperative Inflammatory Markers on the Prognosis of Patients Undergoing Surgical Resection of Pulmonary Oligometastases." Journal of Clinical Medicine 9, no. 10 (2020): 3378. http://dx.doi.org/10.3390/jcm9103378.

Full text

Abstract:

The aim of this study was to assess the prognostic value of preoperative neutrophil-to-lymphocyte ratio (NLR) and C-reactive protein (CRP) levels in patients undergoing resection of pulmonary oligometastases. A retrospective analysis on 141 patients undergoing a first pulmonary metastasectomy in a single center was carried out. Two distinct analysis were performed subdividing patients according to their NLR ratio and CRP level. The main outcomes were survival and time to recurrence. At completion of follow-up 74 patients were still alive (52.5%). Subdividing patients according to their NLR yie

APA, Harvard, Vancouver, ISO, and other styles

12

Seffar, Evan, Brooke Mastrogiacomo, Alex Paynter, et al. "Abstract 1118: The GENIE BPC BRCA Cohort: a real-world repository of standardized clinical and genomic data for young patients with breast cancer." Cancer Research 85, no. 8_Supplement_1 (2025): 1118. https://doi.org/10.1158/1538-7445.am2025-1118.

Full text

Abstract:

Abstract Purpose: The first comprehensive analysis of the detailed clinico-genomic landscape of the breast cancer (BC) cohort of the American Association for Cancer Research (AACR) Project Genomics Evidence Neoplasia Information Exchange (GENIE) Biopharma Collaborative (BPC). Methods: We analyzed 1, 045 BC patients treated at three GENIE-participating institutions. Breast cancer patients in the GENIE registry aged 18-56 at sequencing and with tumor(s) sequenced between 2013 and 2018 were randomly chosen for curation using the PRISSMM framework. Sites of distant metastasis were captured from im

APA, Harvard, Vancouver, ISO, and other styles

13

Dean, Robert M., John W. Sweetenham, Tao Jin, et al. "Risk Factors and Outcomes for Relapse after Autologous Stem Cell Transplantation for Hodgkin Lymphoma." Blood 110, no. 11 (2007): 1903. http://dx.doi.org/10.1182/blood.v110.11.1903.1903.

Full text

Abstract:

Abstract Despite successful outcomes for many patients (pts) with relapsed or refractory Hodgkin lymphoma, disease recurrence leads to a significant number of treatment failures after high-dose chemotherapy with autologous stem cell transplantation (ASCT). Using a prospectively maintained database, a retrospective analysis was conducted in 245 consecutive pts who underwent ASCT for Hodgkin lymphoma from 1985 through 2005 at the Cleveland Clinic Foundation. Objectives were to identify risk factors and outcomes associated with early relapse (within 1 year post ASCT) versus late relapse (over 1 y

APA, Harvard, Vancouver, ISO, and other styles

14

O'Cearbhaill, R., Q. Zhou, A. Iasonos, et al. "Evaluation of the role of aromatase inhibitors (AIs) in the treatment of uterine leiomyosarcoma (uLMS)." Journal of Clinical Oncology 27, no. 15_suppl (2009): 5590. http://dx.doi.org/10.1200/jco.2009.27.15_suppl.5590.

Full text

Abstract:

5590 Background: Although AIs are sometimes used in selected patients with uLMS, there are few data assessing the efficacy of AIs in this setting. Methods: A retrospective electronic medical record review of patients (pts) with uLMS treated with an AI at Memorial Sloan-Kettering Cancer Center between 1998–2008 was performed. The primary endpoint was progression free survival (PFS), defined as time from the start of AI until death, progression or last follow-up. PFS was estimated by Kaplan-Meier method. Best response using RECIST was also assessed. Results: 34 pts with advanced, measurable uLMS

APA, Harvard, Vancouver, ISO, and other styles

15

Mehra, Nikita, Prasanth Ganesan, Venkatraman Radhakrishnan, et al. "Effectiveness of End of Therapy PET Based Deauville Scoring in Predicting Outcomes in Hodgkin's Lymphoma: A Real-World Experience." Blood 132, Supplement 1 (2018): 5921. http://dx.doi.org/10.1182/blood-2018-99-119176.

Full text

Abstract:

Abstract Background: The use of PET CT has become instrumental in the management of Hodgkin's lymphoma (HL), with multiple studies favoring PET adapted therapies. Current guidelines recommend using the Deauville score (DS) for assessment of end therapy PET-CT scans. We looked at the predictive ability of end therapy PET CT DS in a cohort of HL. Methods: Adult patients diagnosed with, and treated for, Hodgkin's lymphoma between 2007 and 2015 with end-of-treatment PET CT scans were included in this retrospective analysis. Results: One hundred and ninety-eight patients [median age- 35 (18-74) yea

APA, Harvard, Vancouver, ISO, and other styles

16

Latypov, V. R., V. S. Popov, V. N. Latypova, S. I. Novikov, D. B. Akhmedov, and O. S. Zebzeeva. "Results of surgical treatment of malignant kidney tumors based on the materials of urology departments of the Siberian State Medical University clinics." Cancer Urology 18, no. 4 (2023): 25–32. http://dx.doi.org/10.17650/1726-9776-2022-18-4-25-32.

Full text

Abstract:

Aim. To analyze the results of treatment of patients with kidney tumors in urology departments of the Siberian State Medical University clinics.Materials and methods. The number of patients with kidney tumors hospitalized in the urology department of the general surgery clinic was 7–10 % of the total annual number of surgical interventions in the urology department. We analyzed 132 cases of malignant kidney tumors. All patients went through imaging and laboratory studies.Results. Treatment results are known in 125 (94.0 %) patients. Mean age of patients was 57.9 years (27 to 86), there were 77

APA, Harvard, Vancouver, ISO, and other styles

17

Jaroszewski, Dawn E., Joanne Xiu, Zoran Gatalica, et al. "PDL-1 and immunohistochemistry markers in esophageal adenocarcinoma." Journal of Clinical Oncology 35, no. 15_suppl (2017): e15567-e15567. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.e15567.

Full text

Abstract:

e15567 Background: Esophageal adenocarcinoma (EAC) prognosis is poor and there is a need to identify patients that benefit most from neoadjuvant therapy. To examine the association of various biomarkers with clinical outcomes in neoadjuvant treatment of EAC, we retrospectively evaluated the biomarker expression (TS, ERCC1, TOPO1, PD-L1, PD-1) in patient matched formalin-fixed paraffin-embedded (FFPE) tumor samples. Methods: Immunohistochemistry of TS (TS106/4H4B1) , ERCC1 (Ab. 8F1), TOPO1 (1D6), PD-L1 (both 22c3 and SP142), PD-1 (NAT105), and chromogenic in-situ hybridization (CISH) of Her2 we

APA, Harvard, Vancouver, ISO, and other styles

18

Wang, J., X. Liu, L. Yang, et al. "Preliminary results from a phase II study of celecoxib plus chemotherapy in patients with untreated advanced NSCLC." Journal of Clinical Oncology 25, no. 18_suppl (2007): 18188. http://dx.doi.org/10.1200/jco.2007.25.18_suppl.18188.

Full text

Abstract:

18188 Background: Preclinical studies indicated that cyclooxygenase-2(cox-2) inhibitor celecoxib may enhance antitumor efficacy of cytotoxics, and combination with chemotherapy had acceptable tolerability in a phase I trial. This phase II trial evaluated the efficacy and safety of the celecoxib plus platinum-based chemotherapy in advanced NSCLC as first-line chemotherapy. Methods: Patients: chemotherapy naïve, IIIB (w/malignant effusion) IV, PS 0–2; treated with platinum-based chemotherapy (Gemcitabine 1,200 mg/m2 d1, 2, Cisplatin 75 mg/m2 d1 Q3w or Docetaxel 35 mg/m2 d1,8,15, cisplatin 75 mg/

APA, Harvard, Vancouver, ISO, and other styles

19

Grill, Jacques, Marie-Cécile Le Deley, Danièle Gambarelli, et al. "Postoperative Chemotherapy Without Irradiation for Ependymoma in Children Under 5 Years of Age: A Multicenter Trial of the French Society of Pediatric Oncology." Journal of Clinical Oncology 19, no. 5 (2001): 1288–96. http://dx.doi.org/10.1200/jco.2001.19.5.1288.

Full text

Abstract:

PURPOSE: To evaluate a strategy that avoids radiotherapy in first-line treatment in children under 5 years of age with brain or posterior fossa ependymoma, by exclusively administering 16 months of adjuvant multiagent chemotherapy after surgery. PATIENTS AND METHODS: Between June 1990 and October 1998, 73 children with ependymoma (82% with high-grade tumors) were enrolled onto this multicenter trial. Children received adjuvant conventional chemotherapy after surgery consisting of seven cycles of three courses alternating two drugs at each course (procarbazine and carboplatin, etoposide and cis

APA, Harvard, Vancouver, ISO, and other styles

20

Whitworth, Pat W., Mark Gittleman, Stephanie Akbari, et al. "Chemosensitivity and endocrine sensitivity prediction by MammaPrint and BluePrint in the Neoadjuvant Breast Registry Symphony Trial (NBRST)." Journal of Clinical Oncology 32, no. 26_suppl (2014): 29. http://dx.doi.org/10.1200/jco.2014.32.26_suppl.29.

Full text

Abstract:

29 Background: Classification into molecular subtypes is important for the selection of therapy for patients with breast cancer. Previous analyses demonstrated that breast cancer subtypes have distinct clinical outcome (Gluck, BCRT 2013). The aim of the prospective NBRST study is to measure chemosensitivity as defined by pathologic complete response (pCR), or endocrine sensitivity as defined by partial response (PR) and metastasis-free survival in molecular subgroups. Methods: The study includes women aged 18 to 90 with histologically proven breast cancer, who are scheduled to start neoadjuvan

APA, Harvard, Vancouver, ISO, and other styles

21

Borel, Christian, Hélène Carinato, Carole Pflumio, et al. "Weekly paclitaxel (P), carboplatin (CP) plus pembrolizumab (PMB) as first-line treatment of recurrent or metastatic (R/M) or locally very advanced (LVA) head and neck squamous cell carcinoma (HNSCC): A retrospective study in 39 patients (pts)." Journal of Clinical Oncology 42, no. 16_suppl (2024): e18018-e18018. http://dx.doi.org/10.1200/jco.2024.42.16_suppl.e18018.

Full text

Abstract:

e18018 Background: Since the results of the KN-048 trial, the combination of platinum/5FU plus PMB has become the standard of care (SOC) for R/M HNSCC pts. The KN-B10 study shows that 5FU can be replaced by P with a favorable response rate and toxicity profile. Weekly use of P reduces hematologic toxicity and increases dose-intensity. Methods: We retrospectively reviewed all records of patients with R/M or LVA (T4b and/or N3b) HNSCC, ECOG-PS 0 to 2, PDL1 CPS ≥ 1, treated in first-line with weekly P (80 mg/m2) and CP (AUC 2: maximum total dose of 250 mg and systematic G-CSF at D3 and D4) for up

APA, Harvard, Vancouver, ISO, and other styles

22

Duong, Hien K., Anna Koo, Lisa Rybicki, et al. "Obese Patients Have Improved Survival Following Autologous Hematopoietic Stem Cell Transplantation." Blood 120, no. 21 (2012): 1989. http://dx.doi.org/10.1182/blood.v120.21.1989.1989.

Full text

Abstract:

Abstract Abstract 1989 High-dose chemotherapy followed by autologous stem cell transplant can improve long-term outcome of patients with hematologic malignancies. Outcomes following transplant are variable. Obesity has implications for stem cell mobilization, chemotherapy administration, and medication dosing. We analyze the impact of obesity on transplant outcomes including neutrophil recovery, platelet recovery, length of hospital stay, and survival. From 1/2004 to 12/2009, 573 patients underwent autologous stem cell transplant. From these patients, 17 were excluded due to incomplete data. O

APA, Harvard, Vancouver, ISO, and other styles

23

Sasaki, Koji, Hagop M. Kantarjian, Susan O'Brien, et al. "Salvage Chemotherapy with Inotuzumab Ozogamicin (INO) Combined with Mini-Hyper-CVD for Adult Patients with Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL)." Blood 126, no. 23 (2015): 3721. http://dx.doi.org/10.1182/blood.v126.23.3721.3721.

Full text

Abstract:

Abstract Background: Outcome of patients with R/R ALL is very poor. INO is a CD22 monoclonal antibody bound to a toxin, calecheamicin, and has shown single-agent activity in R/R ALL with a response rate of 58% and median survival of 6.3 months. The addition of non-myelosuppressive therapy to effective low-intensity chemotherapy might further improve clinical outcome. Methods: Patients ≥18 years with R/R ALL were eligible. The chemotherapy was lower intensity than conventional hyper-CVAD and referred to as mini-hyper-CVD (cyclophosphamide and dexamethasone at 50% dose reduction, no anthracyclin

APA, Harvard, Vancouver, ISO, and other styles

24

Uhm, J. E., J. O. Park, J. Lee, et al. "Pediatric-type sarcomas in adult patients: Age is an independent prognostic factor in IRS group I/II." Journal of Clinical Oncology 24, no. 18_suppl (2006): 9552. http://dx.doi.org/10.1200/jco.2006.24.18_suppl.9552.

Full text

Abstract:

9552 Backgrounds: A number of pediatric sarcomas occur in adults, including Ewing’s sarcoma (EWS)/primitive neuroectodermal tumor (PNET) and rhabdomyosarcoma (RMS). However, these are rare in adult patients (pts) and differ from typical adult sarcomas in that they are generally considered as systemic disease. There is debate as to whether adults do worse than pediatric pts with the same stage of disease. This study was performed to investigate whether various clinical parameters such as tumor size, primary site, age at diagnosis and response to chemotherapy predict the outcome. Methods: 74 con

APA, Harvard, Vancouver, ISO, and other styles

25

Bacigalupo, Andrea, Maurizio Vignola, Teresa Lamparelli, et al. "Long Term Follow up of Two Randomized Trials on Antithymocyte Globulin (ATG) for GVHD Prophylaxis in Unrelated Donor Transplants: Chronic GVHD, Bronchiolitis and Quality of Life." Blood 104, no. 11 (2004): 438. http://dx.doi.org/10.1182/blood.v104.11.438.438.

Full text

Abstract:

Abstract Background . We have reported that rabbit antithymocyte globulin (ATG Sangstat-Genzyme) prevents acute and chronic graft versus host disease (GvHD) in patients undergoing an unrelated donor transplant (Blood2001; 98 (10): 2942–2947). Patients had entered two consecutive randomized trials: in trial-1, 54 patients were randomized to non-ATG (n=25) or 7.5mg/kg rabbit ATG (n=29). In trial-2, 28 patients were randomized in the non-ATG arm and 27 in the ATG 15mg/kg arm. Aim of the study: to assess the risk of extensive chronic GvHD, bronchiolitis obliterans , quality of life, survival and t

APA, Harvard, Vancouver, ISO, and other styles

26

Sayala, Hazem A., Paul Moreton, Ben Kennedy, et al. "Eradication of Minimal Residual Disease with Alemtuzumab in Chronic Lymphocytic Leukemia Is Associated with Prolonged Survival and Is an Appropriate Theraputic Endpoint for Relapsed CLL." Blood 110, no. 11 (2007): 3114. http://dx.doi.org/10.1182/blood.v110.11.3114.3114.

Full text

Abstract:

Abstract Eradication of minimal residual disease (MRD) in chronic lymphocytic leukemia (CLL) is emerging as a desirable therapeutic end point predicting for better outcome. The monoclonal antibody alemtuzumab (Mabcampath) is approved for patients with fludarabine refractory CLL. We previously published 91 patients with relapsed CLL (74 men and 17 women, median age 58 years [range, 32 to 75 years]; 44 fludarabine-refractory) who received a median of 9 weeks (range 1 to 16) of alemtuzumab, 30mg 3x a week after dose escalation, between 1996 and 2003. 84 patients had i.v. alemtuzumab and 7 receive

APA, Harvard, Vancouver, ISO, and other styles

27

Bogani, Giorgio, Fabio Ghezzi, Luis Chiva, et al. "Patterns of recurrence after laparoscopic versus open abdominal radical hysterectomy in patients with cervical cancer: a propensity-matched analysis." International Journal of Gynecologic Cancer 30, no. 7 (2020): 987–92. http://dx.doi.org/10.1136/ijgc-2020-001381.

Full text

Abstract:

ObjectiveRecent evidence has suggested that laparoscopic radical hysterectomy is associated with an increased risk of recurrence in comparison with open abdominal radical hysterectomy. The aim of our study was to identify patterns of recurrence after laparoscopic and open abdominal radical hysterectomy for cervical cancer.MethodsThis a retrospective multi-institutional study evaluating patients with recurrent cervical cancer after laparoscopic and open abdominal surgery performed between January 1990 and December 2018. Inclusion criteria were: age ≥18 years old, radical hysterectomy (type B or

APA, Harvard, Vancouver, ISO, and other styles

28

Matsumoto, Toshihiko, Shogo Yamamura, Tatsuki Ikoma, et al. "Real-World Data of Trifluridine/Tipiracil for Patients With Advanced Gastric Cancer: A Multi-Institutional Retrospective Study." Clinical Medicine Insights: Oncology 16 (January 2022): 117955492211371. http://dx.doi.org/10.1177/11795549221137135.

Full text

Abstract:

Background: A trial with trifluridine/tipiracil (FTD/TPI) versus placebo in patients with heavily pretreated metastatic gastric cancer showed that FTD/TPI is effective with manageable toxicity in these patients. However, real-world data on the effects of FTD/TPI in patients with advanced gastric cancer (AGC) are limited. Methods: We retrospectively collected and analyzed the clinicopathological data of patients with AGC who received FTD/TPI monotherapy at our institutions (Kobe City Medical Center General Hospital, Osaka Red Cross Hospital, Himeji Red Cross Hospital, and Kansai Medical Univers

APA, Harvard, Vancouver, ISO, and other styles

29

Kelley, M. J., J. A. Bogart, L. D. Hodgson, et al. "CALGB 30206: Phase II study of induction cisplatin (P) and irinotecan (I) followed by combination carboplatin (C), etoposide (E), and thoracic radiotherapy for limited stage small cell lung cancer." Journal of Clinical Oncology 25, no. 18_suppl (2007): 7565. http://dx.doi.org/10.1200/jco.2007.25.18_suppl.7565.

Full text

Abstract:

7565 Background: We sought to determine the efficacy of using both irinotecan- and etoposide-containing regimens for patients with untreated LS-SCLC. Methods: Eligibility: measurable disease, performance status (PS) 0–2, no prior therapy, and adequate organ function. Treatment: Induction with P 30 mg/m2 and I 65 mg/m2 both IV day 1 and 8 q21 days ×2 cycles. Beginning day 43 daily chest irradiation (200 cGy/fraction) to 70 Gy concurrent with C AUC=5 IV day 1 and E 100 mg/m2 days 1–3 q 21 days x3 cycles (5 chemotherapy cycles total). Endpoints: Primary - to differentiate a 45% and 60% 2-year sur

APA, Harvard, Vancouver, ISO, and other styles

30

Guillermo, Cecilia, Judith Lipschutz, Juan Zunino, et al. "Autologous Stem Cell Transplantation for NHL: 16 Years Follow- up." Blood 118, no. 21 (2011): 4520. http://dx.doi.org/10.1182/blood.v118.21.4520.4520.

Full text

Abstract:

Abstract Abstract 4520 Between June 1995 and June 2011, we performed 133 Autologous Stem Cell Transplantation (ASCT) in patients with NHL. Long term results of treatment and outcome were analyzed. The data presented were obtained from the Statistical Center of the Center for International Blood and Marrow Transplant Research. Median age was 48 years (range 18–65), 9% ≥ 60 years, 77 males and 55 females. The histology was: 98 (74%) B NHL, Follicular Lymphoma (FL) 26 (20%), Diffuse large B Cell Lymphoma (DLBCL) 47 (35%), Primary Mediastinal Large B Cell Lymphoma 12 (9%), Mantle cell Lymphoma (MC

APA, Harvard, Vancouver, ISO, and other styles

31

Younes, Anas, Anna Sureda, Dina Ben-Yehuda, et al. "Panobinostat in Patients With Relapsed/Refractory Hodgkin's Lymphoma After Autologous Stem-Cell Transplantation: Results of a Phase II Study." Journal of Clinical Oncology 30, no. 18 (2012): 2197–203. http://dx.doi.org/10.1200/jco.2011.38.1350.

Full text

Abstract:

PurposeHodgkin's lymphoma (HL) has no standard of care for patients who are relapsed or refractory to autologous stem-cell transplantation (ASCT). This phase II study examined safety and activity of panobinostat in this population.Patients and MethodsPanobinostat 40 mg was administered orally three times per week. The primary end point was objective response rate (ORR) based on investigator assessment of radiologic imaging. Secondary end points included ORR by independent central review, time to response (TTR), duration of response (DOR), progression-free survival (PFS), overall survival, and

APA, Harvard, Vancouver, ISO, and other styles

32

Marrodan, I., E. Azkona, S. Carrera, et al. "Preoperative chemoradiotherapy with capecitabine and oxaliplatin in patients with locally advanced rectal cancer." Journal of Clinical Oncology 29, no. 4_suppl (2011): 548. http://dx.doi.org/10.1200/jco.2011.29.4_suppl.548.

Full text

Abstract:

548 Background: Locally advanced rectal carcinoma is associated with high rate of abdomino-perineal amputation. We analyzed a cohort of patients (pts) diagnosed of locally advanced rectal cancer, treated with neoadjuvant chemoradiotherapy (QT-RT) with capecitabine and oxaliplatin (XELOX) followed by four cycles of adjuvant XELOX after surgery. Methods: Patients with locally advanced rectal cancer (T3-T4 and/or N+) were treated with oxaliplatin (50mg/m2 day 1, 8, 22 and 29) and capecitabine (1,650mg/m2 on days 1 to 14 and 22 to 35) combined with pelvic radiotherapy (180 cGy/day; 45Gy in 25 frac

APA, Harvard, Vancouver, ISO, and other styles

33

Loupakis, Fotios, Chiara Cremolini, Gianluca Masi, et al. "FOLFOXIRI plus bevacizumab (bev) versus FOLFIRI plus bev as first-line treatment of metastatic colorectal cancer (MCRC): Results of the phase III randomized TRIBE trial." Journal of Clinical Oncology 31, no. 4_suppl (2013): 336. http://dx.doi.org/10.1200/jco.2013.31.4_suppl.336.

Full text

Abstract:

336 Background: First-line FOLFOXIRI demonstrated superior activity and efficacy compared to FOLFIRI. Moreover, the outcome is improved by the addition of bev to first-line doublets. A phase II study of FOLFOXIRI/bev showed promising activity and manageable toxicities. The present trial compared FOLFOXIRI/bev to FOLFIRI/bev as first-line treatment in unresectable mCRC. Methods: Eligibility criteria included: measurable and unresectable mCRC, age 18-75 years, no prior chemotherapy for advanced disease. Patients (pts) were randomized to either FOLFIRI/bev (bev 5 mg/kg, irinotecan 180 mg/sqm, l-L

APA, Harvard, Vancouver, ISO, and other styles

34

Gu, Chengyuan, Ruju Wang, Huizhu Kang, et al. "A prospective study of all-trans retinoic acid plus venetoclax and azacitidine in newly diagnosed acute myeloid leukemia." Journal of Clinical Oncology 42, no. 16_suppl (2024): 6545. http://dx.doi.org/10.1200/jco.2024.42.16_suppl.6545.

Full text

Abstract:

6545 Background: Over the decade, anthracycline and cytarabine-based intensive chemotherapy remains the standard of care for acute myeloid leukemia (AML) but is hampered by serious toxicities like myelosuppression, increased transfusion requirement and disappointing clinical outcomes among the so-called poor-prognosis AML subsets. BCL-2 inhibitor plus azacitidine (AZA) has become a preferred treatment for AML, but the remission rate and overall survival (OS) are suboptimal. Apart from hematologic toxicities, 70.0% of patients were RBC transfusion dependent and 58.6% were platelet transfusion d

APA, Harvard, Vancouver, ISO, and other styles

35

Ceesay, M. Mansour, ZiYi Lim, Michelle Kenyon, et al. "Long Term Outcomes of Adults Undergoing Alemtuzumab-Based Reduced Intensity Conditioning Haematopoietic Stem Cell Transplantation." Blood 110, no. 11 (2007): 1665. http://dx.doi.org/10.1182/blood.v110.11.1665.1665.

Full text

Abstract:

Abstract The use of reduced intensity conditioning regimens (RIC) has facilitated the allografting of older patients while concurrently reducing the transplant-related mortality associated with allogeneic haematopoietic stem cell transplantation. At present, there is limited data available on the longer-term efficacy and safety of RIC HSCT. We performed a retrospective study on the long term outcomes of patients with haematological malignancies who received RIC HSCT at our center over an 8 year period from Jan 1997 to Dec 2005. A total of 263 adult patients received RIC HSCT, of which 135 pati

APA, Harvard, Vancouver, ISO, and other styles

36

Suvannasankha, Attaya, Nizar J. Bahlis, Suzanne Trudel, et al. "Safety and clinical activity of belantamab mafodotin with pembrolizumab in patients with relapsed/refractory multiple myeloma (RRMM): DREAMM-4 Study." Journal of Clinical Oncology 40, no. 16_suppl (2022): 8018. http://dx.doi.org/10.1200/jco.2022.40.16_suppl.8018.

Full text

Abstract:

8018 Background: Belantamab mafodotin (belamaf; BLENREP), a B-cell maturation antigen (BCMA) targeted antibody–drug conjugate approved for adult patients with RRMM, has a multimodal mechanism that eliminates myeloma cells via direct cytotoxicity and a systemic anti-tumor immune response, which may be augmented by an immune checkpoint inhibitor. DREAMM-4 (NCT03848845) assessed safety and clinical activity of belamaf with pembrolizumab (pembro) in RRMM. Methods: This was a Phase I/II, single-arm, open-label study of adults with RRMM after ≥3 lines of therapy (LOT, including anti-CD38 monoclonal

APA, Harvard, Vancouver, ISO, and other styles

37

Suvannasankha, Attaya, Nizar J. Bahlis, Suzanne Trudel, et al. "Safety and clinical activity of belantamab mafodotin with pembrolizumab in patients with relapsed/refractory multiple myeloma (RRMM): DREAMM-4 Study." Journal of Clinical Oncology 40, no. 16_suppl (2022): 8018. http://dx.doi.org/10.1200/jco.2022.40.16_suppl.8018.

Full text

Abstract:

8018 Background: Belantamab mafodotin (belamaf; BLENREP), a B-cell maturation antigen (BCMA) targeted antibody–drug conjugate approved for adult patients with RRMM, has a multimodal mechanism that eliminates myeloma cells via direct cytotoxicity and a systemic anti-tumor immune response, which may be augmented by an immune checkpoint inhibitor. DREAMM-4 (NCT03848845) assessed safety and clinical activity of belamaf with pembrolizumab (pembro) in RRMM. Methods: This was a Phase I/II, single-arm, open-label study of adults with RRMM after ≥3 lines of therapy (LOT, including anti-CD38 monoclonal

APA, Harvard, Vancouver, ISO, and other styles

38

Pare, Amelie, Alexandre Ellis, and Tristan Juette. "Clinicopathological findings of FeLV- positive cats at a secondary referral center in Florida, USA (2008–2019)." PLOS ONE 17, no. 4 (2022): e0266621. http://dx.doi.org/10.1371/journal.pone.0266621.

Full text

Abstract:

Objectives The aim of this study was to describe the seroprevalence, presenting complaint, clinicopathological changes, co-morbidities and outcomes of feline leukemia virus positive cats presented to a specialty referral center in Florida, USA. Methods In this retrospective study, medical records of 8050 cats presented to a private referral center from August 2008 to September 2019 were reviewed. Inclusion criteria required was a positive result for feline leukemia virus by point-of-care antigen testing or immunofluorescence assay. Results Forty-one cases met the inclusion criteria. Of 2002 ca

APA, Harvard, Vancouver, ISO, and other styles

39

Kenter, Gemma, Stefano Greggi, Ignace Vergote, et al. "Results from neoadjuvant chemotherapy followed by surgery compared to chemoradiation for stage Ib2-IIb cervical cancer, EORTC 55994." Journal of Clinical Oncology 37, no. 15_suppl (2019): 5503. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.5503.

Full text

Abstract:

5503 Background: Conflicting evidence on the value of neoadjuvant chemotherapy followed by surgery compared to concomitant chemoradiation in Stage IB2-IIB cervical carcinoma led to this multinational multicenter trial. As the trial is approaching completion of its follow-up, preliminary results are presented. Methods: Between May 2002 and June 2014 a total of 620 patients with FIGO stage Ib2-IIb were randomized between neoadjuvant chemotherapy followed by surgery (NACTS, arm 1, N=311) with standard concomitant chemoradiotherapy (CCRT, arm 2, N=309) . In arm 1, radical hysterectomy was required

APA, Harvard, Vancouver, ISO, and other styles

40

Kalin, Burak, Yvette van Norden, Michel van Gelder, et al. "Panobinostat and decitabine prior to donor lymphocyte infusion in allogeneic stem cell transplantation." Blood Advances 4, no. 18 (2020): 4430–37. http://dx.doi.org/10.1182/bloodadvances.2020002074.

Full text

Abstract:

Abstract Outcome after allogeneic hematopoietic stem cell transplantation (allo-HSCT) is adversely affected by relapse to a considerable degree. To exploit the graft-versus-leukemia effect more effectively, we assessed the feasibility of early initiation of epigenetic therapy with panobinostat and decitabine after allo-HSCT and before donor lymphocyte infusion (DLI) in poor-risk patients with acute myeloid leukemia (AML) or refractory anemia with excess blasts with International Prognostic Scoring System score ≥1.5. A total of 140 poor-risk patients with AML aged 18 to 70 years were registered

APA, Harvard, Vancouver, ISO, and other styles

41

Evens, Andrew M., Chadi Nabhan, Irene Helenowski, et al. "Multicenter Analysis of 150 Very Elderly Non-Hodgkin's Lymphoma (NHL) Patients: Impact of Comorbidities and Response to Initial Therapy on Survival." Blood 116, no. 21 (2010): 3124. http://dx.doi.org/10.1182/blood.v116.21.3124.3124.

Full text

Abstract:

Abstract Abstract 3124 Background: The incidence of NHL increases exponentially with rising age. The most rapidly growing segment of the population is persons > age 65 years, especially > age 80. As a percentage of US population, the age group >80 years has increased by >250% from 1960 to 2000. Furthermore, persons >80 years will more than double within 20 years. However, little data is available regarding the characteristics or outcomes of very elderly NHL patients (pts). Methods: We completed a multicenter retrospective analysis of very elderly NHL pts (=/> 80) diagnosed (d

APA, Harvard, Vancouver, ISO, and other styles

42

Nickenig, C., V. Buecklein, L. H. Lindner, et al. "Ifosfamide, carboplatin, and etoposide (ICE) in combination with regional hyperthermia (RHT) in chemotherapy-pretreated nonresponders with locally advanced high-risk soft tissue sarcoma (HR-STS)." Journal of Clinical Oncology 27, no. 15_suppl (2009): 10581. http://dx.doi.org/10.1200/jco.2009.27.15_suppl.10581.

Full text

Abstract:

10581 Background: Regional hyperthermia (RHT) improves outcome in combination with neoadjuvant chemotherapy as first-line therapy in locally advanced HR-STS (Issels et al., Abstract 10009, ASCO 2007). Efficacy of ICE combined with RHT as second-line treatment strategy in pts with locally advanced HR-STS pretreated with anthracycline-based chemotherapy ± RHT was evaluated. Methods: Between 9/97 and 6/08, 49 pts were treated with ICE + RHT (median age: 51 years, range: 21–74 years), with high-grade (G2 24 pts; G3 25 pts) STS histology (20 Lipo-Sa; 6 Leiomyo-Sa, 6 MPNST, 5 NOS, 2 DSRCT, 10 others

APA, Harvard, Vancouver, ISO, and other styles

43

Takeda, June, Hiroshi Kawabata, Kazunari Aoki, et al. "Clinical Impact of Complex Karyotype, Monosomal Karyotype and Acquisition of Chromosomal Abnormalities in Patients with Myelodysplastic Syndromes." Blood 124, no. 21 (2014): 1907. http://dx.doi.org/10.1182/blood.v124.21.1907.1907.

Full text

Abstract:

Abstract Objectives Despite azacitidine prolonging the survival of patients (pts) with myelodysplastic syndromes (MDS), the overall survival (OS) of those with complex karyotype (CK) or monosomal karyotype (MK) remains dismal, and optimal treatments for these pts have not been established. Furthermore, the prognostic impact of acquisition of additional cytogenetic abnormalities (ACA) during the follow-up periods is poorly understood. In this retrospective study, we aimed to evaluate the prognostic impact of CK, MK, and ACA in MDS pts, and determine optimal treatments. Methods We collected clin

APA, Harvard, Vancouver, ISO, and other styles

44

Lenen, Alicia, Angela J. Waanders, Latifa Bazzi, et al. "LGG-37. A PHASE III STUDY COMPARING TWO CARBOPLATIN CONTAINING REGIMENS FOR CHILDREN AND YOUNG ADULTS WITH PREVIOUSLY UNTREATED LOW-GRADE GLIOMA." Neuro-Oncology 26, Supplement_4 (2024): 0. http://dx.doi.org/10.1093/neuonc/noae064.428.

Full text

Abstract:

Abstract BACKGROUND Low-grade glioma (LGG) is the most common childhood central nervous system tumor. Carboplatin/vincristine (CV) is a standard of care regimen used for incompletely resected tumors. Monthly carboplatin is an alternative regimen that has not been prospectively compared to CV previously in untreated patients. METHODS Patients ≤ 21 years with LGG and no treatment besides surgery were eligible. Patients were stratified according to NF1 status and randomized to Arm A (carboplatin/vincristine) or Arm B (carboplatin monthly). The primary endpoint was 3-year progression-free survival

APA, Harvard, Vancouver, ISO, and other styles

45

Günay, Semra, Berk Gökçek, Özge Kandemir, Arzu Akan, and Orhan Yalçın. "Long-term results of breast cancer patients who received IOERT as boost during BCS: A single-institution retrospective analysis." Turkish Journal of Surgery 39, no. 2 (2023): 115–20. http://dx.doi.org/10.47717/turkjsurg.2023.5978.

Full text

Abstract:

Objective: Intraoperative electron radiotherapy (IOERT) applied as boost to the tumor bed during breast conserving surgery is advantageous in terms of local recurrence in breast cancer patients. In addition, it has other advantages over the adjuvant boost RT such as no risk of tumor bed change, ease of sequencing radiotherapy chemotherapy, and reduced workload of the radiotherapy clinic. This study aimed to evaluate the long-term results of our patients who were treated with this method in our institution and are still being followed up. Material and Methods: One hundred and three patients enr

APA, Harvard, Vancouver, ISO, and other styles

46

Saemann, Lars, Sven Maier, Lisa Rösner, et al. "A Systematic Review with Meta-Analysis Investigating the Impact of Targeted Perfusion Parameters during Extracorporeal Cardiopulmonary Resuscitation in Out-of-Hospital and Inhospital Cardiac Arrest." Journal of ExtraCorporeal Technology 54, no. 3 (2022): 191–202. http://dx.doi.org/10.1051/ject/202254191.

Full text

Abstract:

Evidence regarding perfusion conditions during extracorporeal cardiopulmonary resuscitation (ECPR) is rare. Therefore, we investigated the impact of perfusion parameters on neurologic outcome and survival in patients with in- or out-of-hospital cardiac arrest (IHCA; OHCA) treated with ECPR. We performed a systematic review with meta-analysis. The focus was set on perfusion parameters and their impact on survival and a goal neurological outcome using the cerebral performance category score of 1–2. We conducted random- and mixed-effects meta-analyses and computed pooled estimates and 95% confide

APA, Harvard, Vancouver, ISO, and other styles

47

de Lima, Marcos, Poliana A. Patah, Rima Saliba, et al. "Donor-Recipient Host-Versus-Graft (HVG) HLA Mismatches and Outcome of Cord Blood Transplants (CBT)." Blood 108, no. 11 (2006): 436. http://dx.doi.org/10.1182/blood.v108.11.436.436.

Full text

Abstract:

Abstract The influence of HLA mismatches on outcomes of CBT is yet to be fully defined. We hypothesized that donor-recipient mismatches in the host-versus-graft (HVG) and graft-versus-host (GVH) direction impact engraftment, treatment-related mortality (TRM) and survival after CBT, and addressed the question studying CBT performed in our institution from 3/1996 to June/2006. Methods: 91 patients (pts) were analyzed. Diagnoses were high-risk hematologic malignancies (n=85; 93%) or non-malignant disorders (n=6; 7%). Conditioning was myeloablative (n=86; 95%), while patients not eligible for high

APA, Harvard, Vancouver, ISO, and other styles

48

Guilhot, Francois, François-Xavier Mahon, Joelle Guilhot, et al. "Randomized Comparison of Imatinib Versus Imatinib Combination Therapies in Newly Diagnosed Chronic Myeloid Leukaemia (CML) Patients in Chronic Phase (CP): First Results of the Phase III (SPIRIT) Trial from the French CML Group (FI LMC)." Blood 112, no. 11 (2008): 183. http://dx.doi.org/10.1182/blood.v112.11.183.183.

Full text

Abstract:

Abstract Imatinib (IM) at 400 mg daily is the first line therapy for newly diagnosed CML patients (pts); however, less than 50% of major molecular responses (MMR) are obtained at 12 months. To improve these results, we designed a phase III, multicenter, open-label, prospective randomized trial. The reference arm was IM 400 mg daily (n=159). The 3 experimental arms were IM 600 mg daily (n=160), IM 400mg daily in combination with Ara-C, (20 mg/m2/day, days 15–28 of 28-day cycles)(n=158) and IM 400mg in combination with Peg-IFN alfa-2a (Peg-IFN2a, 90 μg weekly) (n=159). Treatment was delivered at

APA, Harvard, Vancouver, ISO, and other styles

49

Cohen, Yael C., Erel Joffe, Noam Benyamini, et al. "Risk of Progression and Survival in Newly Diagnosed Multiple Myeloma Patients Non-Responsive to Bortezomib-Based Induction Therapy: an Observational Multicenter International Study." Blood 124, no. 21 (2014): 3488. http://dx.doi.org/10.1182/blood.v124.21.3488.3488.

Full text

Abstract:

Abstract INTRODUCTION Botezomib-based induction is widely used and highly effective for the treatment of patients with newly diagnosed multiple myeloma (NDMM), with an overall response rate (ORR) of 75-80%. However, the outcomes of patients who fail to respond to this treatment remain unclear. The goal of this study was to investigate the outcome of patients with NDMM who failed to respond to bortezomib-based induction as compared to induction-responsive patients. METHODS We reviewed consecutive patients with NDMM between 1-JAN-2007 and 31-JAN-2014 in three participating centers in Greece and

APA, Harvard, Vancouver, ISO, and other styles

50

Mamez, Anne-Claire, Amandine Pradier, Sarah Morin-Zorman, et al. "Utility of the 2024 Best Practice Recommendations from the EBMT Cellular Therapy and Immunobiology Working Party for Use of Donor Lymphocyte Infusions after Allogeneic Haematopoietic Stem Cell Transplantation." Blood 144, Supplement 1 (2024): 7177. https://doi.org/10.1182/blood-2024-207834.

Full text

Abstract:

Introduction: Donor lymphocyte infusions (DLI) are a widely employed strategy to increase the graft-versus-tumor (GvT) effect of allogeneic hematopoietic stem cell transplantation (HSCT) and/or to sustain donor engraftment in case of mixed chimerism but can increase non-relapse mortality (NRM) risk mainly secondary to the induction of graft-versus-host disease (GvHD). In recent recommendations (doi:10.1016/S2352-3026(24)00098-X), the EBMT CTIWP (Cellular Therapy and Immunobiology Working Party of the European Society for Blood and Marrow Transplantation) proposed the use of T cell doses adapte

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!